AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Cybin Inc. Common Stock
XNAS · usd
SIC 8290 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00HZ0NJ24
10.19▼ 0.31 (-2.95%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
EBITDA
—
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
Trading Information
Previous Close
10.50
Day's Range
9.87 – 10.75
52-Week Range
3.76 – 15.15
Volume
1.9M
Avg Volume
1.7M
Share Statistics
Shares Outstanding
Employees
50
Exchange
XNAS
Listed
2020-11-10
Share count as of March 31, 2026

Cybin Inc. Common Stock (HELP) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Cybin Inc. Common Stock (HELP)
What is Cybin Inc. Common Stock's Market Cap?
Cybin Inc. Common Stock's Market Cap is $526.1M, based on as-reported figures from SEC (XBRL) filings.
What is Cybin Inc. Common Stock's Enterprise Value?
Cybin Inc. Common Stock's Enterprise Value is $432.2M, based on as-reported figures from SEC (XBRL) filings.
What is Cybin Inc. Common Stock's Net Income (TTM)?
Cybin Inc. Common Stock's Net Income (TTM) is -$78.7M, based on as-reported figures from SEC (XBRL) filings.
What is Cybin Inc. Common Stock's Diluted EPS (TTM)?
Cybin Inc. Common Stock's Diluted EPS (TTM) is -1.52, based on as-reported figures from SEC (XBRL) filings.
What is Cybin Inc. Common Stock's Net Debt?
Cybin Inc. Common Stock's Net Debt is -$93.9M, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · HELPAs-filed SEC (XBRL) data
No Quarterly data available for this company — showing Annual instead. This company files annual reports only — foreign private issuers (Form 20-F / 40-F) are not required to file quarterly reports, so no quarterly figures exist to show.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemMar 31, 2026Mar 31, 2025Mar 31, 2024Mar 31, 2023Mar 31, 2022
EXPENSES
Research
General and administrative costs
Share-based compensation
TOTAL EXPENSES
OTHER INCOME (EXPENSES)
Interest income
Foreign currency translation gain
Other loss
Debt issuance cost
Fair value loss on financial instruments
TOTAL OTHER INCOME (LOSS)
NET LOSS FOR THE YEAR